Ionis Pharmaceuticals announced positive Phase 3 data for olezarsen, its antisense drug targeting severe hypertriglyceridemia (sHTG). The pivotal CORE and CORE2 trials showed up to 72% placebo-adjusted reductions in fasting triglycerides and an 85% decrease in acute pancreatitis events. The drug was well tolerated, with mostly mild injection site reactions. This success supports Ionis’ plan to submit for label expansion to include severe hypertriglyceridemia beyond its original rare familial chylomicronemia syndrome indication. The drug addresses a growing market due to rising obesity and diabetes prevalence. Investor enthusiasm propelled Ionis shares up over 30%.